On Tuesday, Shares of Liberty Property Trust (NYSE:LPT), gained 1.72% to $35.99.
Liberty Property Trust, stated that funds from operations accessible to common shareholders (diluted) for the first quarter of 2015 was $0.70 per share, contrast to $0.58 per share for the first quarter of 2014.
Net income per common share (diluted) was $0.21 per share for the quarter ended March 31, 2015, contrast to $0.49 per share (diluted) for the quarter ended March 31, 2014. Net income for the 2015 period reflects gain on sale of $0.02 per share, contrast with $0.31 per share for the 2014 period.
Operating results for the first quarter of 2015 comprise:
- Termination fees of $3.8 million,
- A gain related to the sale by a joint venture of a land leasehold interest in Cambridge, United Kingdom, Liberty’s share of which was $4.8 million,
- G&A expense of $4.0 million (contrast to $3.9 million for the first quarter of 2014) of additional compensation expense related to the accelerated vesting of long-term incentive compensation.
Liberty Property Trust is a publicly owned real estate investment holding trust. Through its partner, it provides leasing, property administration, development, acquisition, and other tenant-related services for a portfolio of industrial and office properties.
Shares of Canadian Solar Inc. (NASDAQ:CSIQ), gained 1.70% to $35.85, during its last trading session.
Canadian Solar, declared that it is planned to attend 2015 CICC Conference on Tuesday, April 21 to Wednesday, April 22, 2015 at the Waldorf Astoria Hotel in New York City.
During the conference, Dr. Shawn Qu, Canadian Solar’s Chairman and Chief Executive Officer will take part in a clean energy panel to talk about assessment and outlook of photovoltaics, alternative energy vehicles and battery technologies on the afternoon of April 22, 2015.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar module products worldwide. The company operates in two segments, Module and Project.
At the end of Tuesday’s trade, Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), gained 1.70% to $120.70, hitting its highest level.
Alnylam Pharmaceuticals, declared initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP). These new clinical data are being presented at the 67th Annual Meeting of the American Academy of Neurology (AAN) being held April 18 – 25 in Washington, D.C. Study results showed a mean 2.5 point decrease in modified Neuropathy Impairment Score (mNIS+7) at 12 months in patients who had reached the 12-month endpoint (N=20) at the time of data cutoff. This decrease in neuropathy progression compares favorably to the 13 to 18 point raise in mNIS+7 at 12 months that can be estimated from the literature in untreated FAP patients with similar baseline characteristics. In addition, patisiran treatment achieved a sustained mean serum TTR knockdown at the 80% target level for about 16 months, with an up to 88% mean knockdown achieved between doses. In aggregate, these results are consistent with the therapeutic hypothesis that TTR knockdown has the potential to halt neuropathy progression in patients with FAP. Patisiran was also found to be generally well tolerated out to 17 months of drug administration, with no drug-related serious adverse events to date; all 27 patients enrolled in the study continue to receive patisiran. Alnylam has also declared that it plans to report 18-month OLE data in late 2015.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs comprise Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders;
Finally, UTi Worldwide Inc. (NASDAQ:UTIW), ended its last trade with 1.69% gain, and closed at $9.32.
UTi Worldwide, has designated new leaders for two of UTi’s 16 freight forwarding area teams.
Raymond Lee joined UTi effective 1 February as the leader of the Greater China area (China, Hong Kong and Taiwan). He is based in UTi’s Shanghai office and brings more than 25 years of experience in freight forwarding and contract logistics, having held leadership roles in operations, products and sales. In his previous roles, he held full profit and loss responsibility for a competitor in China and Southeast Asia; he was responsible for freight administration throughout the Asia Pacific region; and he was actively involved in operational excellence and business transformation, counting the implementation of a new operating system in 13 of the Asia Pacific countries.
David Buss joined UTi effective 16 March as the leader of the North America area (Canada and United States). He is based in UTi’s Chicago office and brings more than 22 years of supply chain leadership experience, having held senior forwarding positions with responsibility for both sales and operations for two competitors. In these positions he achieved exceptional results by surpassing growth aims and opening new offices while maintaining fiscal and operating discipline. Formerly he served as a business development manager for another competitor and he started his career in supply chain sales with companies in Houston and Los Angeles. David holds a B.S. in Finance from California State University-Long Beach and a J.D. from Thomas Jefferson School of Law in San Diego.
UTi Worldwide Inc. operates as a non-asset-based supply chain services and solutions company. It operates through two segments, Freight Forwarding, and Contract Logistics and Distribution. The Freight Forwarding segment offers airfreight forwarding, ocean freight forwarding, customs brokerage, and other related services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
